These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27236153)

  • 41. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence.
    Kondili LA; Lala A; Gunson B; Hubscher S; Olliff S; Elias E; Bramhall S; Mutimer D
    Eur J Surg Oncol; 2007 Sep; 33(7):868-73. PubMed ID: 17258882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
    Ng KT; Liu J; Yeung OW; Pang L; Shiu HC; Liu H; Yang XX; Chan AC; Wong TC; Lo CM; Man K
    Hepatol Int; 2023 Dec; 17(6):1596-1609. PubMed ID: 37542605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
    Hepatology; 2019 Mar; 69(3):1193-1205. PubMed ID: 30548884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.
    Wang J; Bao J; Wang R; Hong J; Zhang L; Que Q; Xu S; Wu Y; Zhan Q; Liu Y; Liu J; Zheng S; Ling S; Xu X
    World J Surg Oncol; 2023 Mar; 21(1):104. PubMed ID: 36967432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients.
    Sánchez-Lorencio MI; Saenz L; Ramirez P; Villalba-López F; de la Orden V; Mediero-Valeros B; Revilla Nuin B; Gonzalez MR; Cascales-Campos PA; Ferreras-Martínez D; Noguera-Velasco JA; Díaz-Rubio E; Parrilla P
    Transplant Proc; 2018 Mar; 50(2):623-627. PubMed ID: 29579870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP-Score.
    Menahem B; Duvoux C; Ganne N; Mallat A; Seror O; Calderaro J; Launoy G; Alves A; Cherqui D; Luciani A; Laurent A
    World J Surg; 2019 Jan; 43(1):221-229. PubMed ID: 30128773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
    Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
    Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
    Li JH; Chen T; Xing H; Li RD; Shen CH; Zhang QB; Tao YF; Wang ZX
    Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):245-252. PubMed ID: 35534342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.
    Hakeem AR; Young RS; Marangoni G; Lodge JP; Prasad KR
    Aliment Pharmacol Ther; 2012 May; 35(9):987-99. PubMed ID: 22429190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
    Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
    BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
    Wongjarupong N; Negron-Ocasio GM; Chaiteerakij R; Addissie BD; Mohamed EA; Mara KC; Harmsen WS; Theobald JP; Peters BE; Balsanek JG; Ward MM; Giama NH; Venkatesh SK; Harnois DM; Charlton MR; Yamada H; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
    World J Gastroenterol; 2018 Mar; 24(12):1321-1331. PubMed ID: 29599607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
    Schraiber LDS; de Mattos AA; Zanotelli ML; Cantisani GPC; Brandão ABM; Marroni CA; Kiss G; Ernani L; Marcon PDS
    Medicine (Baltimore); 2016 Jan; 95(3):e2478. PubMed ID: 26817881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.
    Vidal RIO; Vidal EIO; Pereira BB; Assane CC; Ribeiro A; do Nascimento EM; Romeiro FG; Ribeiro Filho J
    Biomed Res Int; 2020; 2020():1487593. PubMed ID: 33134370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.